Company intelligence
KalVista Pharmaceuticals, Inc.
Advancing novel medicines to empower everyday lives.
About KalVista Pharmaceuticals, Inc.
For nearly a decade, KalVista Pharmaceuticals has been focused on addressing the critical unmet needs of those living with hereditary angioedema (HAE). With more than 250 employees worldwide, we leverage our team’s vast knowledge and expertise across all aspects of research, development, and commercialization to redefine the future of HAE treatment and advance global care for those who need it most.
Verified activity
Signals from KalVista Pharmaceuticals, Inc.
5 published signals
Presence & Recognition
KalVista Pharmaceuticals, Inc. is attending the 8th Bradykinin Symposium in Berlin, focusing on the kallikrein-kinin system and hereditary angioedema care.
Reported by KalVista Pharmaceuticals, Inc.
Products & Services
KalVista Pharmaceuticals, Inc. successfully launched EKTERLY.
Reported by Keith Tennison
Presence & Recognition
KalVista Pharmaceuticals, Inc. was recognized by Fierce Pharma.
Reported by Keith Tennison
Presence & Recognition
KalVista Pharmaceuticals, Inc. supported the Hereditary Angioedema Association - HAEA Grassroots Advocacy Network that met this summer in Washington D.C.
Reported by KalVista Pharmaceuticals, Inc.
Presence & Recognition
KalVista Pharmaceuticals, Inc. was named a 2026 Prix Galien USA nominee in the Best Product for Rare/Orphan Diseases category
Reported by KalVista Pharmaceuticals, Inc.